Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Sees Significant Drop in Short Interest

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) was the target of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totaling 33,109 shares, a decrease of 55.5% from the December 15th total of 74,418 shares. Based on an average daily trading volume, of 265,842 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the shares of the company are sold short. Approximately 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 265,842 shares, the short-interest ratio is presently 0.1 days.

Xtant Medical Stock Performance

XTNT traded up $0.01 during trading on Friday, reaching $0.67. 124,205 shares of the company were exchanged, compared to its average volume of 172,353. Xtant Medical has a 52 week low of $0.34 and a 52 week high of $0.95. The company has a current ratio of 2.21, a quick ratio of 1.06 and a debt-to-equity ratio of 0.35. The firm has a 50 day moving average of $0.70 and a 200 day moving average of $0.68. The stock has a market cap of $93.10 million, a P/E ratio of 66.57 and a beta of -0.08.

Xtant Medical (NYSEAMERICAN:XTNT) last released its quarterly earnings results on Monday, November 10th. The medical device company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.02. The business had revenue of $27.77 million during the quarter, compared to analyst estimates of $32.70 million. Xtant Medical had a net margin of 1.32% and a return on equity of 3.77%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of XTNT. Jane Street Group LLC bought a new stake in shares of Xtant Medical during the 2nd quarter worth $26,000. Mink Brook Asset Management LLC raised its position in shares of Xtant Medical by 125.8% during the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock worth $81,000 after purchasing an additional 60,997 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Xtant Medical by 4.6% during the third quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock valued at $1,529,000 after purchasing an additional 104,159 shares during the last quarter. Crescent Grove Advisors LLC boosted its position in shares of Xtant Medical by 94.3% in the 2nd quarter. Crescent Grove Advisors LLC now owns 412,024 shares of the medical device company’s stock valued at $304,000 after purchasing an additional 200,000 shares during the period. Finally, AWM Investment Company Inc. purchased a new position in Xtant Medical in the 2nd quarter worth about $4,875,000. 69.33% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, BTIG Research lowered their price objective on shares of Xtant Medical from $2.00 to $1.50 and set a “buy” rating on the stock in a research report on Tuesday, November 11th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $1.50.

About Xtant Medical

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.